Synopsis: Taking a tablet twice daily instead of chemotherapy may turn chronic lymphocytic leukemia (CLL) into a highly treatable disease.
(Codenamed GS-1101 or CAL-101) - A drug under investigation for the treatment of chronic lymphocytic leukaemia. It is in Phase III clinical trials testing drug combinations with rituximab and/or bendamustine as of 2013. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.
Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating chemotherapy.
CLL is the most common form of leukemia, a cancer of the white blood cells. Some 16,000 Americans are diagnosed with CLL annually, and about 5,000 die of it each year.
"The treatment today for CLL can be worse than the disease, leading to a great deal of side effects and death. This study, and others we have conducted on idelalisib, demonstrates that we may no longer need to use chemotherapy in CLL," says the lead investigator, Dr. Richard R. Furman, the Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medical College and a hematologist/oncologist at NewYork-Presbyterian/Weill Cornell Medical Center. "Even if this cancer remains incurable, it now can be treated as if it was a chronic disease with a pill, in the same way that high blood pressure is treated."
CLL is a cancer of B cells, which normally produce antibodies to fight infections. In CLL, B cells grow out of control, accumulating in all of a patient's organs. Patients are typically treated with a combination of chemotherapeutic drugs, to which they commonly respond. Unfortunately, patients ultimately relapse and require repeated cycles of chemotherapy. With each relapse, the remissions become shorter until the patient either no longer responds, or is forced to stop taking the drugs because of their side effects, which are a result of the medications' inability to differentiate between healthy cells and cancer cells.
In this randomized, double-blinded study, researchers from 19 medical centers in five countries tested a combination of two targeted drugs - medications that attack cancer without damaging healthy cells. They compared rituximab and idelalisib against rituximab and a placebo pill in 220 CLL patients who could not receive chemotherapy.
They found that those who received the combination of idelalsib and rituximab went longer without their disease worsening than those who received only rituximab, which has been the standard of care. Six months into the study, cancers in 93 percent of participants in the combination therapy group had not worsened, compared to 46 percent of those in the rituximab plus placebo group.
What's more, just 13 percent of patients treated with rituximab alone responded to the therapy, compared to 81 percent of the participants in the idelalisib treatment group. A higher percentage of patients who received both drugs - some 92 percent - were still alive a year after the study began, compared to 80 percent of those who only received rituximab. About the same percentage of patients in each group suffered side effects from the treatments.
The contrast was so significant that an independent data-monitoring committee halted the study early, in October 2013, so that all of the study participants could receive idelalisib.
"We saw incredible responses in patients who used idelalisib. Their cancer quickly melted away," says Dr. Furman, who is also director of Weill Cornell's CLL Research Center and an associate professor of medicine. "These types of responses were even seen in patients who didn't respond to chemotherapy."
Chemotherapy-resistant patients are typically the most difficult patients to treat. "It is remarkable how quickly idelalisib worked in this heavily treated group of patients, many of whom were resistant to chemotherapy. We saw responses within a week," Dr. Furman says.
Previous studies led by Weill Cornell Medical College have shown equally significant results in newly diagnosed CLL patients and in those who could tolerate chemotherapy.
"Having a treatment like idelalisib, which is highly effective and well tolerated, and thus can generate responses in patients that are unable to tolerate treatment and unlikely to respond, indicates the potential for idelalisib in all patients," Dr. Furman says.
Idelalisib is the second targeted drug that Dr. Furman has tested that shows strong activity against CLL. He also studied ibrutinib in a phase 2 clinical trial reported last July in the New England Journal of Medicine. Both drugs, known as tyrosine kinase inhibitors, work on different targets within the same molecular pathway.
Ibrutinib was approved for use in mantle cell lymphoma (another B cell lymphoma) in November by the U.S. Food and Drug Administration. Because it targets B cells, Dr. Furman is using the drug as a first-line treatment for all of his CLL patients - even those who are newly diagnosed. "I am now able to avoid all use of chemotherapy in these patients, which has long been my goal," he says.
Dr. Furman believes idelalisib and ibrutinib will become the treatments of choice for all B cell lymphomas. "These drugs will change the lives of many patients," he says. "Given the long-term toxicities of chemotherapy, leading to bone marrow failure, infections, and death, moving this therapy up front in the treatment algorithm and providing it to all patients is the next step."
The study was funded by Gilead, for which Dr. Furman has served as an adviser.
Dr. Furman's co-authors include co-first authors Drs. Jeff P. Sharman, US Oncology Research, Springfield, OR, and Steven E. Coutre, University School of Medicine, Stanford, CA; Dr. Nicole Lamanna, Columbia University Medical Center; Dr. Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Dr. John M. Pagel, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Dr. Peter Hillmen, St. James's University Hospital, Leeds, United Kingdom; Dr. Jacqueline C. Barrientos, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY; Dr. Andrew D. Zelenetz, Memorial Sloan-Kettering Cancer Center, New York, NY; Dr. Thomas J. Kipps, University of California San Diego, Moores Cancer Center, La Jolla, CA; Dr. Ian Flinn, Sarah Cannon Research Institute, Nashville, TN; Dr. Paolo Ghia, Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milano, Italy; Dr. Herbert Eradat, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Dr. Thomas Ervin, Florida Cancer Specialists, Englewood, FL; Bertrand Coiffier, Center Hospitalier Lyon-Sud, Pierre-Benite, France; Dr. Andrew R. Pettitt, Royal Liverpool University Hospital, Liverpool, United Kingdom; Dr. Shuo Ma, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Dr. Stephan Stilgenbauer, University of Ulm, Ulm, Germany; Maria Aiello, Dave M. Johnson, Langdon L. Miller, and Drs. Daniel Li, Thomas M. Jahn and Roger D. Dansey, Gilead Sciences, Inc., Foster City, CA; Drs. Paula Cramer and Michael Hallek, University of Cologne, Cologne, Germany; Dr. Susan M. O'Brien, University of Texas MD Anderson Cancer Center, Houston, TX.